Angina market seen reaching $14.84 billion by 2030

The Business Research Company says the global angina market will grow from $11.36 billion in 2025 to $12.05 billion in 2026, then to $14.84 billion by 2030. The report points to rising cardiovascular disease rates, wider use of cardiac diagnostics and therapies, and stronger demand in Asia-Pacific.

Why it matters: - Angina treatment demand rises as cardiovascular disease becomes more common worldwide. - The market outlook signals sustained spending on cardiac drugs, diagnostics and care delivery through 2030. - Regional growth could shift toward Asia-Pacific, even as North America remains the largest market.

What happened: - The Business Research Company published an angina market report covering market size, trends and a global forecast for 2026-2035. - The report puts the global angina market at $11.36 billion in 2025. - The market is expected to reach $12.05 billion in 2026. - The report forecasts the market will grow to $14.84 billion by 2030. - North America held the largest share of the global angina market in 2025. - Asia-Pacific is expected to post the fastest growth over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample is available here. - The full report is available here.

The details: - The market is projected to grow at a 6.1% CAGR from 2025 to 2026. - The report expects a 5.3% CAGR from 2026 onward. - Recent growth has been driven by higher cardiovascular disease incidence. - Wider availability of beta blockers and nitrates has supported demand. - Hospital cardiac care expansion has added treatment capacity. - Better diagnostic testing has lifted detection and treatment. - Growth in specialized cardiology services has also supported the market. - Future growth is expected to come from personalized cardiovascular therapies. - More minimally invasive cardiac interventions are expected to support demand. - Digital cardiac monitoring adoption is projected to increase. - Preventive cardiology initiatives are expected to broaden. - Cardiovascular drug development is expected to advance further. - Key trends include combination drug treatments, longer-acting nitrates, preventive cardiac care, expanded interventional options and closer attention to lifestyle and risk factor management. - Angina pectoris is chest pain or discomfort caused by insufficient blood supply to the heart muscle. - Blockages or narrowing of the coronary arteries commonly cause the reduced blood flow. - Atherosclerosis, or plaque buildup in arterial walls, is a common underlying cause. - The market report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The report ties market growth to both disease burden and treatment access, which suggests demand is being shaped by diagnosis rates as well as clinical need. - The fastest growth forecast for Asia-Pacific points to expanding healthcare capacity and treatment adoption outside the largest current market. - The emphasis on preventive care, monitoring and minimally invasive procedures suggests angina management is moving toward earlier intervention and broader chronic disease control. - The report cites a sharp rise in cardiovascular disease deaths reported by the US Centers for Disease Control and Prevention in October 2024, from 371,506 in 2022 to 919,032 in 2023.

What's next: - The market is expected to keep expanding through 2030 as demand grows for therapies, monitoring and intervention tools. - Preventive cardiology and digital monitoring are likely to become more important in treatment pathways. - Regional growth in Asia-Pacific may continue to narrow the gap with North America if forecast trends hold. - The Business Research Company is offering direct access to the report and sample materials for buyers evaluating the category.